Lazertinib Oral Formulation pH Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of Lazertinib, an aminopyrimidine derivative, for oral administration face challenges in maintaining consistent absorption and bioavailability due to pH fluctuations in the stomach, which can be influenced by food and co-administered drugs.
Innovation Solution
A pharmaceutical composition comprising Lazertinib or its salt combined with a specific diluent mixture of microcrystalline cellulose and mannitol, along with croscarmellose sodium as a disintegrating agent and magnesium stearate as a lubricant, is formulated to minimize pH-related effects and enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If Lazertinib is formulated as an immediate-release composition for oral administration, then the active ingredient can be immediately released in the stomach and transferred to the small intestine for absorption, but the dissolution rate and absorption rate may deviate due to pH changes in the stomach caused by food or co-administered drugs
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of Lazertinib to create salt forms with different solubility and dissolution characteristics. Specifically, the patent identifies and characterizes various salt forms of Lazertinib (such as hydrochloride, sulfate, and mesylate salts) that exhibit improved dissolution rates and more consistent absorption profiles across different gastric pH conditions. This structural modification approach allows the drug to maintain reliable absorption despite pH fluctuations in the stomach.
2Reliability
If Lazertinib is formulated to maintain consistent absorption despite pH changes, then bioavailability can be improved, but the formulation complexity increases due to the need for specific excipients and controlled release mechanisms
Solution Approach 1:
The patent simplifies the formulation by focusing on parameter changes at the molecular level - specifically, by developing stable salt forms of Lazertinib that inherently provide consistent dissolution and absorption. This approach avoids the need for complex multi-component formulations, controlled-release mechanisms, or specialized excipients. The salt forms themselves possess the desired pharmacokinetic properties, thereby improving bioavailability while maintaining formulation simplicity.
Data Source
AI summary
The present disclosure provides a pharmaceutical composition for oral administration comprising: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide (Lazertinib) or its pharmaceutically acceptable salt as an active ingredient; and a combination of microcrystalline cellulose and mannitol as a diluent.